WO2008070344A3 - Compositions and methods for binding sphingosine-1-phosphate - Google Patents

Compositions and methods for binding sphingosine-1-phosphate Download PDF

Info

Publication number
WO2008070344A3
WO2008070344A3 PCT/US2007/082647 US2007082647W WO2008070344A3 WO 2008070344 A3 WO2008070344 A3 WO 2008070344A3 US 2007082647 W US2007082647 W US 2007082647W WO 2008070344 A3 WO2008070344 A3 WO 2008070344A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphate
compositions
methods
binding sphingosine
sip
Prior art date
Application number
PCT/US2007/082647
Other languages
French (fr)
Other versions
WO2008070344A2 (en
WO2008070344A9 (en
Inventor
Roger A Sabbadini
William A Garland
Genevieve Hansen
Steven Tarran Jones
David Gareth Williams
Original Assignee
Lpath Therapeutics Inc
Roger A Sabbadini
William A Garland
Genevieve Hansen
Steven Tarran Jones
David Gareth Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK07871262.7T priority Critical patent/DK2087002T3/en
Priority to MX2009004532A priority patent/MX2009004532A/en
Application filed by Lpath Therapeutics Inc, Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams filed Critical Lpath Therapeutics Inc
Priority to JP2009534885A priority patent/JP5795833B2/en
Priority to PL07871262T priority patent/PL2087002T3/en
Priority to CA002667574A priority patent/CA2667574A1/en
Priority to EP07871262.7A priority patent/EP2087002B1/en
Priority to ES07871262.7T priority patent/ES2524059T3/en
Priority to CN200780048665.8A priority patent/CN101679506B/en
Priority to BRPI0718118A priority patent/BRPI0718118A2/en
Priority to SI200731525T priority patent/SI2087002T1/en
Priority to AU2007329759A priority patent/AU2007329759B2/en
Publication of WO2008070344A2 publication Critical patent/WO2008070344A2/en
Publication of WO2008070344A9 publication Critical patent/WO2008070344A9/en
Priority to US12/258,355 priority patent/US8025877B2/en
Priority to US12/258,346 priority patent/US8222373B2/en
Priority to US12/258,337 priority patent/US8067549B2/en
Priority to US12/258,383 priority patent/US8026342B2/en
Priority to US12/258,353 priority patent/US7956173B2/en
Publication of WO2008070344A3 publication Critical patent/WO2008070344A3/en
Priority to IL198379A priority patent/IL198379A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

The present invention relates to anti-SIP agents, for example, humanized monoclonal antibodies, and their uses for detection of SIP or for treatment of diseases and conditions associated with SIP.
PCT/US2007/082647 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate WO2008070344A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AU2007329759A AU2007329759B2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
SI200731525T SI2087002T1 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
JP2009534885A JP5795833B2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
MX2009004532A MX2009004532A (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate.
CA002667574A CA2667574A1 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
EP07871262.7A EP2087002B1 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
ES07871262.7T ES2524059T3 (en) 2006-10-27 2007-10-26 Compositions and procedures of binding to sphingosine-1-phosphate
CN200780048665.8A CN101679506B (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
BRPI0718118A BRPI0718118A2 (en) 2006-10-27 2007-10-26 compositions and methods for sphingosine-1-phosphate binding
DK07871262.7T DK2087002T3 (en) 2006-10-27 2007-10-26 Compositions and Methods for Binding Sphingosine-1-Phosphate
PL07871262T PL2087002T3 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate
US12/258,355 US8025877B2 (en) 2006-10-27 2008-10-24 Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate
US12/258,346 US8222373B2 (en) 2006-10-27 2008-10-24 Humanized antibodies and compositions for binding sphingosine-1-phosphate
US12/258,337 US8067549B2 (en) 2006-10-27 2008-10-24 Humanized antibodies and compositions for binding sphingosine-1-phosphate
US12/258,383 US8026342B2 (en) 2006-10-27 2008-10-24 Compositions and methods for binding sphingosine-1-phosphate
US12/258,353 US7956173B2 (en) 2006-10-27 2008-10-24 Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate
IL198379A IL198379A (en) 2006-10-27 2009-04-26 Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85497106P 2006-10-27 2006-10-27
US60/854,971 2006-10-27

Publications (3)

Publication Number Publication Date
WO2008070344A2 WO2008070344A2 (en) 2008-06-12
WO2008070344A9 WO2008070344A9 (en) 2008-08-28
WO2008070344A3 true WO2008070344A3 (en) 2008-11-20

Family

ID=39492938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082647 WO2008070344A2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate

Country Status (18)

Country Link
US (6) US7829674B2 (en)
EP (1) EP2087002B1 (en)
JP (2) JP5795833B2 (en)
KR (1) KR101581279B1 (en)
CN (2) CN101679506B (en)
AU (1) AU2007329759B2 (en)
BR (1) BRPI0718118A2 (en)
CA (1) CA2667574A1 (en)
DK (1) DK2087002T3 (en)
ES (1) ES2524059T3 (en)
IL (1) IL198379A (en)
MX (1) MX2009004532A (en)
PL (1) PL2087002T3 (en)
PT (1) PT2087002E (en)
RU (1) RU2460541C2 (en)
SI (1) SI2087002T1 (en)
WO (1) WO2008070344A2 (en)
ZA (1) ZA200902860B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
CN101687031B (en) * 2006-10-27 2014-05-14 勒帕斯公司 Compositions and methods for treating ocular diseases and conditions
WO2009108633A2 (en) * 2008-02-25 2009-09-03 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CA2745436A1 (en) * 2008-12-05 2010-06-10 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2400981A4 (en) * 2009-02-26 2013-02-27 Lpath Inc Humanized platelet activating factor antibody design using anti-lipid antibody templates
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
HUE038451T2 (en) 2009-08-06 2018-10-29 Hoffmann La Roche Method to improve virus removal in protein purification
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
WO2011109650A1 (en) * 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
US9102718B2 (en) * 2010-04-30 2015-08-11 Lpath, Inc. Anti-S1P antibody treatment of patients with ocular disease
US20130344087A1 (en) * 2010-06-06 2013-12-26 Roger A. Sabbadini Combinations of anti-s1p antibodies and shpingolipid pathway inhibitors
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012072715A2 (en) * 2010-12-01 2012-06-07 Universität Zürich Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
JP5766958B2 (en) * 2011-01-21 2015-08-19 オリンパス株式会社 Microscope system, information processing apparatus, and information processing program
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
CN103748450A (en) 2011-08-19 2014-04-23 马尔文仪器有限公司 Dual-mode characterization of particulates
CN104411725B (en) 2012-07-04 2018-09-28 弗·哈夫曼-拉罗切有限公司 Anti-biotin antibodies and application method
KR102090849B1 (en) * 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 Covalently linked antigen-antibody conjugates
ES2600154T3 (en) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2787006B1 (en) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
MX2016015280A (en) 2014-06-26 2017-03-03 Hoffmann La Roche Anti-brdu antibodies and methods of use.
US10793592B2 (en) * 2014-11-06 2020-10-06 Merck Patent Gmbh Activated carbon for the removal of leachables and/or extractables
US9754383B1 (en) * 2014-12-22 2017-09-05 Flagship Biosciences, Inc. Automated methods for assessment of celiac disease
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN105820250B (en) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 A kind of anti-BASIGIN humanized antibody and its application
EP3554258B1 (en) 2016-12-15 2023-07-19 Société des Produits Nestlé S.A. Compositions and methods that modulate phosphorus or enzymes in a companion animal
CN110945128B (en) 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 Compositions and methods for treating pulmonary fibrosis
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534323B1 (en) * 1997-06-10 2003-03-18 Medlyte Diagnostics, Inc. Compositions and methods for early detection of heart disease
WO2006078336A2 (en) * 2004-10-28 2006-07-27 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1073471B (en) 1958-09-02 1960-01-21 Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) Process for the production of azelaic acid
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
SE455445B (en) 1984-08-28 1988-07-11 Pharmacia Ab ANTIBODIES AGAINST SIALOSYL LACTOTETRAUS (IV? 723NEUACLCOSE? 714) AND THE ANTIBODY'S RESPONSE ANTIGEN'S USE IN TUMOR DIAGNOSTICS
EP0173648A3 (en) 1984-08-30 1988-04-27 Ciba-Geigy Ag New monoclonal antibodies to glycoconjugates, processes for their production, and applications
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE3741056A1 (en) 1987-12-04 1989-08-24 Behringwerke Ag MANUMYCINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5248824A (en) 1990-12-31 1993-09-28 The Biomembrane Institute Method of preparing N,N,N-trimethylsphingosine
US5137919A (en) 1990-12-31 1992-08-11 Biomembrane Institute Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5677288A (en) 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
DE69333082T2 (en) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City OBTAINING HOMOZYGOTEM BY TARGETED GENETIC EVENTS
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5260288A (en) 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5369030A (en) 1992-09-11 1994-11-29 Duke University Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
WO1995013818A1 (en) 1993-11-15 1995-05-26 Baker Medical Research Institute A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
DK0742789T3 (en) 1994-02-02 2000-11-13 Liposome Co Inc Pharmaceutically active compounds and liposomes and methods for their use
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5585476A (en) 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
US5627171A (en) 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5667337A (en) 1995-09-15 1997-09-16 Lazes; Richard J. Rotating containment and repelling boom and method for confining a material floatable on a liquid surface
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
JPH09110722A (en) 1995-10-20 1997-04-28 Toray Ind Inc Immunoliposome for transducing tumorous cell of antitumor active substance and its preparation
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5830916A (en) 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
DE19621038A1 (en) 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidines, processes for their preparation and medicaments containing these compounds
EP0940409B1 (en) 1996-07-19 2004-05-12 Takara Shuzo Co. Ltd. Process for the preparation of sphingolipids and sphingolipid derivatives
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6140060A (en) 1996-12-12 2000-10-31 Chun; Jerold J. M. Cloned lysophosphatidic acid receptors
US5919687A (en) 1996-12-24 1999-07-06 John Hopkins University Recombinant N-SMases and nucleic acids encoding same
DE69832987T2 (en) 1997-03-12 2006-07-27 Takara Bio Inc., Otsu SPINGOSINANALOGA
EP1021546A1 (en) 1997-08-11 2000-07-26 Memorec Stoffel GmbH Neutral sphingomyelinase
US5989803A (en) 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
WO1999012890A1 (en) 1997-09-11 1999-03-18 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
PT1034298E (en) 1997-12-05 2012-02-03 Scripps Research Inst Humanization of murine antibody
US6057126A (en) 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
JP2002501751A (en) 1998-01-29 2002-01-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー New compound
CA2320117A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
HUP0004505A3 (en) 1998-02-16 2002-09-30 Kitasato Inst Novel substances kf-1040 and process for producing the same
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
CA2323787A1 (en) 1998-03-13 1999-09-16 Wayne Marasco Humanized antibody and uses thereof
US6130067A (en) 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
WO1999061581A2 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
DE19828850A1 (en) 1998-06-27 1999-12-30 Gvs Ges Fuer Erwerb Und Verwer New sphingolipid desaturase that selectively introduces double bond into sphingolipids and capnoids
US6352844B1 (en) 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
DE19847149A1 (en) 1998-10-13 2000-04-20 Max Planck Gesellschaft New pseudoceramide compounds useful for skin cleansing and care comprise N-acyl 2-amino-1-alkanol or 1-amino-2-alkanol derivatives
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
CA2348488C (en) 1999-01-05 2011-03-01 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders
WO2000052173A2 (en) 1999-03-02 2000-09-08 Nps Allelix Corp. Cloned human sphingosine kinase homologues
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
US6608185B1 (en) 1999-03-25 2003-08-19 Kitasato Institute Substances KF-1040T4A,KF-1040T4B, KF-1040T5A, and KF-1040T5B, and process for producing same
US6830919B1 (en) 1999-03-26 2004-12-14 Takara Bio Inc. Ceramidase gene
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
JP2000293181A (en) 1999-04-12 2000-10-20 Daiichikosho Co Ltd Karaoke singing equipment having features in lyrics picture extracting function
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
KR100798375B1 (en) 1999-05-13 2008-01-28 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 Sphingosine kinase enzyme
DE19924148A1 (en) 1999-05-26 2000-12-07 Univ Heidelberg Sphingomyelinase inhibitors
WO2001004139A2 (en) 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
IT1307786B1 (en) 1999-07-22 2001-11-19 Bracco Spa CERAMID ANALOGS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-TUMORAL.
BR0015138A (en) 1999-10-28 2002-07-16 Warner Lambert Co Human sphingosine kinase gene
AU1548101A (en) 1999-11-24 2001-06-04 Sagami Chemical Research Center Sphingosine derivatives
AU2001233086A1 (en) 2000-01-28 2001-08-07 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
US6667163B2 (en) 2000-02-07 2003-12-23 Merck & Co., Inc. Polynucleotide sequences encoding mouse sphingosine-1-phosphate phosphatase
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
AU2001238283C1 (en) 2000-02-14 2006-02-02 Curagen Corporation Sphingosine kinases
JP2001261575A (en) 2000-03-13 2001-09-26 General Hospital Corp Method for regulating vasoconstriction and its composition
WO2001071045A2 (en) 2000-03-23 2001-09-27 Millennium Pharmaceuticals, Inc. High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
JP2003528851A (en) 2000-03-28 2003-09-30 ザ リポソーム カンパニー、インコーポレーテッド Ceramide derivatives and methods of use
AU2001255477A1 (en) 2000-04-19 2001-11-07 The Trustees Of Columbia University In The City Of New York Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration
AUPQ744700A0 (en) 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
US20030125533A1 (en) 2000-10-06 2003-07-03 Sophia Kossida Regulation of human sphingosine kinase-like protein
US6881546B2 (en) 2000-12-22 2005-04-19 Medlyte, Inc., Sdsu Heart Institute Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020150582A1 (en) 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7611851B2 (en) * 2004-07-27 2009-11-03 Merck & Co., Inc. Canis sphingosine 1-phosphate receptor isoform 1
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
CN101687031B (en) * 2006-10-27 2014-05-14 勒帕斯公司 Compositions and methods for treating ocular diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534323B1 (en) * 1997-06-10 2003-03-18 Medlyte Diagnostics, Inc. Compositions and methods for early detection of heart disease
WO2006078336A2 (en) * 2004-10-28 2006-07-27 Lpath Therapeutics, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases

Also Published As

Publication number Publication date
PL2087002T3 (en) 2015-02-27
EP2087002A4 (en) 2010-06-30
US20090148443A1 (en) 2009-06-11
KR20100043137A (en) 2010-04-28
IL198379A (en) 2015-04-30
JP2010515427A (en) 2010-05-13
US20100003242A1 (en) 2010-01-07
PT2087002E (en) 2014-11-26
MX2009004532A (en) 2009-09-04
BRPI0718118A2 (en) 2017-05-30
US8067549B2 (en) 2011-11-29
US8025877B2 (en) 2011-09-27
AU2007329759B2 (en) 2013-05-30
ES2524059T3 (en) 2014-12-03
AU2007329759A1 (en) 2008-06-12
EP2087002B1 (en) 2014-09-24
CN101679506B (en) 2015-02-25
WO2008070344A2 (en) 2008-06-12
ZA200902860B (en) 2010-07-28
CN104650225A (en) 2015-05-27
US8026342B2 (en) 2011-09-27
RU2009120052A (en) 2010-12-10
US7829674B2 (en) 2010-11-09
US20090130100A1 (en) 2009-05-21
US20090137037A1 (en) 2009-05-28
US7956173B2 (en) 2011-06-07
DK2087002T3 (en) 2014-10-27
RU2460541C2 (en) 2012-09-10
US8222373B2 (en) 2012-07-17
US20090010922A1 (en) 2009-01-08
JP5795833B2 (en) 2015-10-14
KR101581279B1 (en) 2015-12-31
IL198379A0 (en) 2011-08-01
EP2087002A2 (en) 2009-08-12
US20090130099A1 (en) 2009-05-21
JP2015134760A (en) 2015-07-27
JP6053834B2 (en) 2016-12-27
CN104650225B (en) 2019-10-01
CA2667574A1 (en) 2008-06-12
SI2087002T1 (en) 2014-11-28
WO2008070344A9 (en) 2008-08-28
CN101679506A (en) 2010-03-24

Similar Documents

Publication Publication Date Title
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2009112245A9 (en) Antibody against the csf-1 r
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007127317A3 (en) Humanized c-kit antibody
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008116219A3 (en) Uses of monoclonal antibody 8h9
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2008079246A3 (en) Cd44 antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2008097439A3 (en) Anti-autoimmune antibodies for treatment of pemphigus
WO2009048537A3 (en) Humanized antibody
WO2011004028A3 (en) Tlr3 binding agents
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048665.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871262

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2667574

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 198379

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2009534885

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004532

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2832/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007329759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097010728

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009120052

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007871262

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007329759

Country of ref document: AU

Date of ref document: 20071026

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0718118

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090327